All News
Inflammatory Arthritis and Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by
Read Article
Biosimilar Bonanza in 2023 (12.9.2022)
Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow.com.
Read Article
Telemedicine Updates
Several recent articles inform us of recent trends in Telemedicine.
Read Article
ACR Urges Congress to Prioritize Medicare Pay Cuts, Prior Authorization, and Telehealth
As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R.
Read Article
Eosinophilia in systemic JIA patients after exposure to biologics
Dr. Bella Mehta discusses Abstract 0872 at #ACR22.
https://t.co/FI7KfDURr3 https://t.co/FqnqMPHJ3h
Links:
Dr. John Cush RheumNow ( View Tweet)
Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE
https://t.co/qJ8YbJ2Y6A https://t.co/deZKc1835I
Links:
Dr. John Cush RheumNow ( View Tweet)
Joint hypermobility linked to depression & anxiety? Longitudinal Study of 6105 kids at age 14 yrs: 19% had generalised joint hypermobility (more in F) *+& assoc w/ depression (OR: 3.53), anxiety (3.14) at age 18 https://t.co/9NrEfwt4L5 https://t.co/JrM2JKUuJ0
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsia [aOR 2.12] , peripartum cardiomyopathy (4.42), CHF (4), arrhythmias (2.2), AKI (7.7), stroke (4.8), VTE (6.9) w/ incr hosp costs https://t.co/PF6P8oDWZB https://t.co/jA2pHcciB1
Links:
Dr. John Cush RheumNow ( View Tweet)
Xeljanz Cancer Risks Detailed
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
https://t.co/OG2OkD5Tcw https://t.co/1dZcJ5jDUj
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab Efficacy in TNF-Refractory PsA
Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors.
https://t.co/NCJvhmisNe https://t.co/Tk2d7ILHl2
Links:
Dr. John Cush RheumNow ( View Tweet)
From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab
Links:
Dr. John Cush RheumNow ( View Tweet)
3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/ksdPcH9W0O https://t.co/OvI9wytf5H
Links:
Dr. John Cush RheumNow ( View Tweet)
Oligoarticular PsA: FOREMOST Study
Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study
https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk
Links:
Dr. John Cush RheumNow ( View Tweet)
Sensor-engineered glove evaluates hand function in RA
Dr. David Liew discusses abstract 0904 at ACR22 Convergence. Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis
https://t.co/e5VCOC56BC https://t.co/vfuVWMrqSj
Links:
Dr. John Cush RheumNow ( View Tweet)
Netherlands study of 220 consecutive inflammatory arthritis pts enrolled in electronic remote telehealth monitoring showed that 141 (64%) dropped out, with a median dropout at 17 wks ( moreso in women). Why? Simple is not alway simple... https://t.co/nziKil4vas https://t.co/oyyulMnIu1
Links:
Dr. John Cush RheumNow ( View Tweet)
National cohort of 20–39-yr old men - among ~1.3 million, 18,473 Dx w/ gout (incidence 3.36/1,000 PY). Developing metabolic syndr doubled #gout risk (aHR 2.31); MetS at all visits had 4x risk (aHR 3.82) & MetS recovery reduced gout risk by 59% https://t.co/bLmf1AL5VI https://t.co/8c47zk6vqu
Links:
Dr. John Cush RheumNow ( View Tweet)
Top 10 Pharma Revenues 2021:
1 J&J $93.77 billion (USD)
2 Pfizer $81.29 B
3 Roche $68.7 B
4 AbbVie S$56.2 B
5 Novartis $51.63 B
6 Merck $48.7 B
7 BMS $46.4 B
8 GSK $43.57 B
9. Sanofi $44.67 B
10. AstraZeneca $37.47 B
https://t.co/ptFAyk4S5S https://t.co/cCtPboI53x
Links:
Dr. John Cush RheumNow ( View Tweet)
Goofy or Novel: "How gravity may cause irritable bowel syndrome". A hypothesis, published in the American Journal of Gastroenterology, describes how the intestines, spine, heart, nerves and brain evolved to manage gravity. https://t.co/lLyAkruyyy? https://t.co/TJH8Du8rm6
Links:
Dr. John Cush RheumNow ( View Tweet)
Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines
Following the 2016 American Academy of Ophthalmology Guidelines, rheums have dutifully reduced the dose of HCQ taken by patients with SLE to some number south of 5mg/kg per day.
https://t.co/iToRttwPbC https://t.co/REpWkI7vC0
Links:
Dr. John Cush RheumNow ( View Tweet)
A Multidimensional Approach in the Management of Axial Spondylarthritis
Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis.
https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo
Links:
Dr. John Cush RheumNow ( View Tweet)